Cargando…

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

Detalles Bibliográficos
Autores principales:	Olesinski, Elyse A., Bhatia, Karanpreet S., Mahesh, Aarthi N., Rosli, Shazwina, Mohamed, Jameelah S., Jen, Wei Y., Jain, Nitin, Garcia, Jacqueline S., Wong, Gee C., Ooi, Melissa, Letai, Anthony, Konopleva, Marina, Bhatt, Shruti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285538/ https://www.ncbi.nlm.nih.gov/pubmed/36763538 http://dx.doi.org/10.1182/bloodadvances.2022007728

Ejemplares similares

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models
por: Olesinski, Elyse A., et al.
Publicado: (2021)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
por: Potter, Danielle S., et al.
Publicado: (2021)

Mutual Regulation of Bcl-2 Proteins Independent of the BH3 Domain as Shown by the BH3-Lacking Protein Bcl-x(AK)
por: Plötz, Michael, et al.
Publicado: (2012)

Antagonizing Bcl-2′s BH4 domain in cancer
por: Vervloessem, Tamara, et al.
Publicado: (2015)

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
por: Le Pen, J, et al.
Publicado: (2016)

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
por: Le Pen, J, et al.
Publicado: (2017)

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia
por: Iacovelli, Stefano, et al.
Publicado: (2015)

BCL2DB: database of BCL-2 family members and BH3-only proteins
por: Rech de Laval, Valentine, et al.
Publicado: (2014)

BH4 domain peptides derived from Bcl-2/Bcl-XL as novel tools against acute pancreatitis
por: Vervliet, Tim, et al.
Publicado: (2018)

Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells
por: Foight, Glenna Wink, et al.
Publicado: (2014)

Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
por: Oakes, SR, et al.
Publicado: (2012)

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
por: Deng, Jiusheng, et al.
Publicado: (2016)

BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
por: Ramesh, Prashanthi, et al.
Publicado: (2020)

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2016)

A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
por: Lavik, Andrew R., et al.
Publicado: (2015)

The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist
por: Rautureau, G J P, et al.
Publicado: (2012)

Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Kanakaveti, Vishnupriya, et al.
Publicado: (2022)

Ryanodine receptors are targeted by anti-apoptotic Bcl-X(L) involving its BH4 domain and Lys87 from its BH3 domain
por: Vervliet, Tim, et al.
Publicado: (2015)

Structural Investigation of Orf Virus Bcl-2 Homolog ORFV125 Interactions with BH3-Motifs from BH3-Only Proteins Puma and Hrk
por: Suraweera, Chathura D., et al.
Publicado: (2021)

Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
por: Liu, Qian, et al.
Publicado: (2019)

Molecular Interactions of Prodiginines with the BH3 Domain of Anti-Apoptotic Bcl-2 Family Members
por: Hosseini, Ali, et al.
Publicado: (2013)

The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation
por: Singh, Amandeep, et al.
Publicado: (2018)

BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy
por: Nougarède, Adrien, et al.
Publicado: (2018)

Bcl-2 regulates pyroptosis and necroptosis by targeting BH3-like domains in GSDMD and MLKL
por: Shi, Chong-Shan, et al.
Publicado: (2019)

Competition Between Phenothiazines and BH3 Peptide for the Binding Site of the Antiapoptotic BCL-2 Protein
por: do Carmo, Aline Lagoeiro, et al.
Publicado: (2020)

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
por: Benito, Juliana M., et al.
Publicado: (2015)

Selective regulation of IP(3)-receptor-mediated Ca(2+) signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl
por: Monaco, G, et al.
Publicado: (2012)

Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma
por: Potter, Danielle S., et al.
Publicado: (2023)

Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER(+) breast cancer
por: Deng, Jing, et al.
Publicado: (2013)

Why do BCL-2 inhibitors work and where should we use them in the clinic?
por: Montero, Joan, et al.
Publicado: (2018)

Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak
por: Uren, Rachel T., et al.
Publicado: (2007)

Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme
por: Cartron, P F, et al.
Publicado: (2012)

Domain-specific insight into the recognition of BH3-death motifs by the pro-survival Bcl-2 protein
por: Mushtaq, Ameeq Ul, et al.
Publicado: (2022)

A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020)

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021)

Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1
por: Jenson, Justin M, et al.
Publicado: (2017)

bcl‐2 Regulation in Normal Resting Lymphocytes and Lymphoblasts
por: Kendo, Eisaku, et al.
Publicado: (1994)

Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions
por: Finnegan, N M, et al.
Publicado: (2001)

Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity
por: Wilson-Annan, Julie, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_r8bv22on3uhl9f1ehm8jl7r5ps